A roundup of manufacturing news from Bavarian Nordic and Pfizer. Highlights below. 

* Bavarian Nordic in $157-M Supply Pact with US Gov’t for Smallpox/Mpox vaccine 
* Pfizer Investing $99 M To Expand Mfg in Australia 

---

Bavarian Nordic in $157-M Supply Pact with US Gov’t for Smallpox/Mpox vaccine 
Bavarian Nordic, a Hellerup (near Copenhagen), Denmark-based vaccine company, has has received a new supply order, valued at $156.8 million, from the US government to manufacture additional bulk product for Jynneos, the company’s smallpox/mpox vaccine. 

The agreement is with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services. 

The bulk product, representing $139.7 million of the contract value, will be manufactured and invoiced in 2024 and will partly replenish the inventory used to manufacture vaccines in response to the mpox outbreak in 2022. Replenishment of the bulk inventory is necessary to fulfil the company’s existing contract to supply a freeze-dried version of the vaccine for US smallpox preparedness. The contract also includes approximately $17 million for additional services in the period 2025-2027, including storage of vaccine doses in the US. 

Bavarian Nordic formed agreements with the US government to supply Jynneos in 2022 and 2023 and supplied approximately 7 million doses of the vaccine across the two years. 

Source: Bavarian Nordic 

---

Pfizer Investing $99 M To Expand Mfg in Australia 
Pfizer is investing AU$150 million (US$99 million) to upgrade its manufacturing facility in Melbourne, Victoria, Australia, for producing new antimicrobial treatments. 

Upgrades included the construction of a new separate facility that hosts two newly installed lyophilizers, which are used in the antimicrobial manufacturing process. The site has also been selected for a trial of artificial intelligence technology designed to support key site processes. 

The site upgrades are on track to complete installation work and be operational by mid-2025, with commercial manufacture commencing in 2026. 

Source: Pfizer